6:@0.028028:0.039294:0.041081:0.039294:0.041081:0.019261:0.028028:0.019261:0.000000
Drug-class overview:@0.097196:0.039084:0.342800:0.039084:0.342800:0.019649:0.097196:0.019649:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS :@0.097141:0.974259:0.701335:0.974259:0.701335:0.960936:0.097141:0.960936:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.701335:0.974259:0.705081:0.974259:0.705081:0.960936:0.701335:0.960936:0.000000
VOLUME 1:@0.705252:0.974259:0.786566:0.974259:0.786566:0.959690:0.705252:0.959690:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1-2 minutes of the second dose   an additional :@0.096970:0.096840:0.479970:0.096840:0.479970:0.081852:0.096970:0.081852:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.355857:0.096324:0.364670:0.096324:0.364670:0.081640:0.355857:0.081640:0.000000
 :@0.475756:0.096840:0.479970:0.096840:0.479970:0.081852:0.475756:0.081852:0.000000
or higher dose is not recommended. :@0.096970:0.112715:0.381392:0.112715:0.381392:0.097727:0.096970:0.097727:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Contraindications::@0.096970:0.132903:0.254757:0.132903:0.254757:0.116512:0.096970:0.116512:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6:@0.254755:0.127124:0.260981:0.127124:0.260981:0.117568:0.254755:0.117568:0.000000
Second- or third-degree av block and sick sinus :@0.096970:0.148639:0.479932:0.148639:0.479932:0.133651:0.096970:0.133651:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
syndrome except in patients with a functional :@0.096970:0.164369:0.479951:0.164369:0.479951:0.149380:0.096970:0.149380:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
artificial pacemaker :@0.096970:0.180098:0.250139:0.180098:0.250139:0.165110:0.096970:0.165110:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Side effects::@0.096970:0.200286:0.200186:0.200286:0.200186:0.183895:0.096970:0.183895:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6:@0.200184:0.194507:0.206411:0.194507:0.206411:0.184951:0.200184:0.184951:0.000000
Headache :@0.096970:0.216022:0.178807:0.216022:0.178807:0.201033:0.096970:0.201033:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.194971:0.215506:0.203784:0.215506:0.203784:0.200822:0.194971:0.200822:0.000000
  dizziness :@0.203784:0.216022:0.298380:0.216022:0.298380:0.201033:0.203784:0.201033:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.314543:0.215506:0.323356:0.215506:0.323356:0.200822:0.314543:0.200822:0.000000
  lightheadedness :@0.323356:0.216022:0.479970:0.216022:0.479970:0.201033:0.323356:0.201033:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.475756:0.216022:0.479970:0.216022:0.479970:0.201033:0.475756:0.201033:0.000000
:@0.096970:0.231236:0.105783:0.231236:0.105783:0.216551:0.096970:0.216551:0.000000
 transient or rapid and spontaneous worsening :@0.105783:0.231752:0.479970:0.231752:0.479970:0.216763:0.105783:0.216763:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of intracranial hypertension   apprehensiveness :@0.096970:0.247481:0.479970:0.247481:0.479970:0.232492:0.096970:0.232492:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.319700:0.246965:0.328513:0.246965:0.328513:0.232281:0.319700:0.232281:0.000000
:@0.096970:0.262695:0.105783:0.262695:0.105783:0.248010:0.096970:0.248010:0.000000
 blurred vision   Metallic taste   nausea   Facial :@0.105783:0.263211:0.479990:0.263211:0.479990:0.248222:0.105783:0.248222:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.221506:0.262695:0.230319:0.262695:0.230319:0.248010:0.221506:0.248010:0.000000
:@0.343407:0.262695:0.352220:0.262695:0.352220:0.248010:0.343407:0.248010:0.000000
:@0.419472:0.262695:0.428285:0.262695:0.428285:0.248010:0.419472:0.248010:0.000000
flushing    bradycardia and severe bradycardia :@0.096989:0.278940:0.480028:0.278940:0.480028:0.263951:0.096989:0.263951:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.168936:0.278424:0.177749:0.278424:0.177749:0.263740:0.168936:0.263740:0.000000
requiring temporary pacing    asystole   Sinus :@0.097008:0.294670:0.479990:0.294670:0.479990:0.279681:0.097008:0.279681:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.327417:0.294154:0.336230:0.294154:0.336230:0.279469:0.327417:0.279469:0.000000
:@0.417413:0.294154:0.426226:0.294154:0.426226:0.279469:0.417413:0.279469:0.000000
pause    av block   Cardiovascular disorders :@0.096989:0.310399:0.480009:0.310399:0.480009:0.295410:0.096989:0.295410:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.155024:0.309883:0.163837:0.309883:0.163837:0.295199:0.155024:0.295199:0.000000
:@0.261434:0.309883:0.270247:0.309883:0.270247:0.295199:0.261434:0.295199:0.000000
 :@0.475795:0.310399:0.480009:0.310399:0.480009:0.295410:0.475795:0.295410:0.000000
:@0.097008:0.325613:0.105821:0.325613:0.105821:0.310928:0.097008:0.310928:0.000000
 atrial or ventricular fibrillation   torsade de pointes :@0.105821:0.326128:0.480028:0.326128:0.480028:0.311140:0.105821:0.311140:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.326993:0.325613:0.335806:0.325613:0.335806:0.310928:0.326993:0.310928:0.000000
 :@0.475795:0.326128:0.480009:0.326128:0.480009:0.311140:0.475795:0.311140:0.000000
:@0.097008:0.341342:0.105821:0.341342:0.105821:0.326658:0.097008:0.326658:0.000000
 dyspnoea   bronchospasm   Hyperventilation :@0.105821:0.341858:0.480028:0.341858:0.480028:0.326869:0.105821:0.326869:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.196203:0.341342:0.205016:0.341342:0.205016:0.326658:0.196203:0.326658:0.000000
:@0.332073:0.341342:0.340886:0.341342:0.340886:0.326658:0.332073:0.326658:0.000000
:@0.097027:0.357072:0.105840:0.357072:0.105840:0.342387:0.097027:0.342387:0.000000
 thoracic constricting feeling   Chest pains or :@0.105840:0.357587:0.480047:0.357587:0.480047:0.342599:0.105840:0.342599:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.344004:0.357072:0.352817:0.357072:0.352817:0.342387:0.344004:0.342387:0.000000
pressure    burning sensation   Head pressure :@0.097047:0.373317:0.480047:0.373317:0.480047:0.358328:0.097047:0.358328:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.171303:0.372801:0.180116:0.372801:0.180116:0.358117:0.171303:0.358117:0.000000
:@0.342637:0.372801:0.351450:0.372801:0.351450:0.358117:0.342637:0.358117:0.000000
:@0.097047:0.388530:0.105860:0.388530:0.105860:0.373846:0.097047:0.373846:0.000000
  arm heaviness    back neck and arm pain :@0.105860:0.389046:0.480086:0.389046:0.480086:0.374058:0.105860:0.374058:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.246810:0.388530:0.255623:0.388530:0.255623:0.373846:0.246810:0.373846:0.000000
 :@0.475833:0.389046:0.480047:0.389046:0.480047:0.374058:0.475833:0.374058:0.000000
:@0.097047:0.404260:0.105860:0.404260:0.105860:0.389576:0.097047:0.389576:0.000000
 Sweating    discomfort feeling   Injection-site :@0.105860:0.404776:0.480105:0.404776:0.480105:0.389787:0.105860:0.389787:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.191950:0.404260:0.200763:0.404260:0.200763:0.389576:0.191950:0.389576:0.000000
:@0.360263:0.404260:0.369076:0.404260:0.369076:0.389576:0.360263:0.389576:0.000000
infections:@0.097066:0.420505:0.171976:0.420505:0.171976:0.405517:0.097066:0.405517:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Special precautions:  :@0.097066:0.440693:0.279511:0.440710:0.279511:0.424319:0.097066:0.424302:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6:@0.269398:0.434925:0.275624:0.434925:0.275624:0.425370:0.269398:0.425370:0.000000
the possibility of increased conduction down :@0.096978:0.456439:0.479959:0.456439:0.479959:0.441451:0.096978:0.441451:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
abnormal  pathways  in  patients  with  atrial :@0.096978:0.472169:0.479940:0.472169:0.479940:0.457180:0.096978:0.457180:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
fibrillation or flutter and an accessory pathway :@0.096978:0.487898:0.479998:0.487898:0.479998:0.472910:0.096978:0.472910:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.096978:0.503112:0.105791:0.503112:0.105791:0.488428:0.096978:0.488428:0.000000
 eCG abnormal at time of conversion   do not :@0.105791:0.503628:0.479978:0.503628:0.479978:0.488639:0.105791:0.488639:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.405049:0.503112:0.413862:0.503112:0.413862:0.488428:0.405049:0.488428:0.000000
administer concomitantly with dipyridamole :@0.096978:0.519357:0.479959:0.519357:0.479959:0.504369:0.096978:0.504369:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.096978:0.534571:0.105791:0.534571:0.105791:0.519887:0.096978:0.519887:0.000000
  use in pregnancy and lactation only where :@0.105791:0.535087:0.479978:0.535087:0.479978:0.520098:0.105791:0.520098:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
absolutely necessary   Compatibility  with other :@0.096978:0.550816:0.479978:0.550816:0.479978:0.535828:0.096978:0.535828:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.265791:0.550300:0.274604:0.550300:0.274604:0.535616:0.265791:0.535616:0.000000
medications unknown   Qt interval prolongation :@0.096978:0.566546:0.479998:0.566546:0.479998:0.551557:0.096978:0.551557:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.274258:0.566030:0.283071:0.566030:0.283071:0.551345:0.274258:0.551345:0.000000
:@0.096978:0.581759:0.105791:0.581759:0.105791:0.567075:0.096978:0.567075:0.000000
  bronchospasm with possible precipitation :@0.105791:0.582275:0.479998:0.582275:0.479998:0.567287:0.105791:0.567287:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
or aggravation in patients with severe chronic :@0.096978:0.598005:0.479959:0.598005:0.479959:0.583016:0.096978:0.583016:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
obstructive pulmonary lung disease :@0.096978:0.613734:0.376377:0.613734:0.376377:0.598746:0.096978:0.598746:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Drug interactions::@0.096978:0.633922:0.251937:0.633922:0.251937:0.617531:0.096978:0.617531:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6:@0.251927:0.628152:0.258153:0.628152:0.258153:0.618596:0.251927:0.618596:0.000000
dipyridamole may potentiate the action :@0.096970:0.649667:0.479990:0.649667:0.479990:0.634678:0.096970:0.634678:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of adenosine. Methyalxanthines are strong :@0.096970:0.665397:0.479951:0.665397:0.479951:0.650408:0.096970:0.650408:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
adenosine inhibitors. Interacts with drugs :@0.096970:0.681126:0.479951:0.681126:0.479951:0.666137:0.096970:0.666137:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
intended to improve cardiac conduction. High :@0.096970:0.696856:0.479970:0.696856:0.479970:0.681867:0.096970:0.681867:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
degree of heart block possible in the presence of :@0.096970:0.712585:0.479990:0.712585:0.479990:0.697596:0.096970:0.697596:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
carbamazepine. Possible torsade de pointes risk :@0.096970:0.728315:0.480009:0.728315:0.480009:0.713326:0.096970:0.713326:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
in patients with prolonged Qt interval, whether :@0.096970:0.744044:0.479970:0.744044:0.479970:0.729055:0.096970:0.729055:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
congenital or acquired as a consequence of drug-:@0.096970:0.759773:0.475718:0.759773:0.475718:0.744785:0.096970:0.744785:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
induced or metabolic sequelae:@0.096970:0.775503:0.334883:0.775503:0.334883:0.760514:0.096970:0.760514:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
REfEREnCES:@0.097162:0.806962:0.209807:0.806962:0.209807:0.790571:0.097162:0.790571:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1.:@0.096970:0.821012:0.108293:0.821012:0.108293:0.807689:0.096970:0.807689:0.000000:0.000000
Cooper:@0.127278:0.821012:0.177907:0.821012:0.177907:0.807689:0.127278:0.807689:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
MJ.:@0.201135:0.821012:0.223063:0.821012:0.223063:0.807689:0.201135:0.807689:0.000000:0.000000:0.000000
assessment:@0.246291:0.821012:0.326715:0.821012:0.326715:0.807689:0.246291:0.807689:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of:@0.349926:0.821012:0.363507:0.821012:0.363507:0.807689:0.349926:0.807689:0.000000:0.000000
efficacy:@0.386734:0.821012:0.438954:0.821012:0.438954:0.807689:0.386734:0.807689:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of:@0.462182:0.821012:0.475763:0.821012:0.475763:0.807689:0.462182:0.807689:0.000000:0.000000
pharmacotherapy for ventricular tachycardia. :@0.127278:0.835417:0.436183:0.835417:0.436183:0.822094:0.127278:0.822094:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Heart, :@0.436149:0.835417:0.478841:0.835417:0.478841:0.822329:0.436149:0.822329:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Lung and Circulation.:@0.127278:0.849823:0.266730:0.849823:0.266730:0.836734:0.127278:0.836734:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.266730:0.849823:0.270356:0.849823:0.270356:0.835688:0.266730:0.835688:0.000000
2007;16(3):170-5.:@0.270356:0.849823:0.385264:0.849823:0.385264:0.836499:0.270356:0.836499:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2.   vukmir rb. Cardiac arrhythmia therapy. :@0.096970:0.864228:0.388650:0.864228:0.388650:0.850904:0.096970:0.850904:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
The American :@0.387367:0.864228:0.478841:0.864228:0.478841:0.851140:0.387367:0.851140:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Journal of Emergency Medicine.:@0.127278:0.878633:0.332274:0.878633:0.332274:0.865545:0.127278:0.865545:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.332274:0.878633:0.335900:0.878633:0.335900:0.864498:0.332274:0.864498:0.000000
1995;13(4):459-70.:@0.335900:0.878633:0.459154:0.878633:0.459154:0.865309:0.335900:0.865309:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
3.   thireau J, Pasquié J-l, Martel  e,  le Guennec J-Y, :@0.096970:0.893038:0.479509:0.893038:0.479509:0.879715:0.096970:0.879715:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
richard S. new drugs vs. old concepts: a fresh look :@0.127278:0.907443:0.479526:0.907443:0.479526:0.894120:0.127278:0.894120:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
at antiarrhythmics. :@0.127278:0.921848:0.258503:0.921848:0.258503:0.908525:0.127278:0.908525:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Pharmacology and Therapeutics.:@0.259923:0.921848:0.475780:0.921848:0.475780:0.908760:0.259923:0.908760:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.475780:0.921848:0.479406:0.921848:0.479406:0.907713:0.475780:0.907713:0.000000
2011;132:125-45.:@0.127278:0.936253:0.241467:0.936253:0.241467:0.922930:0.127278:0.922930:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
4.   Workman  aJ, Smith Gl,  rankin  aC. Mechanisms :@0.524254:0.095078:0.906793:0.095078:0.906793:0.081755:0.524254:0.081755:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of termination and prevention of atrial fibrillation :@0.554562:0.108872:0.906827:0.108872:0.906827:0.095548:0.554562:0.095548:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
by  drug  therapy. :@0.554562:0.122524:0.678535:0.122524:0.678535:0.109201:0.554562:0.109201:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Pharmacology and Therapeutics. :@0.682708:0.122524:0.906125:0.122524:0.906125:0.109436:0.682708:0.109436:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2011;131(2):221-41.:@0.554562:0.136318:0.686163:0.136318:0.686163:0.122994:0.554562:0.122994:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5.   Yang F, Hanon  S,  lam P, Schweitzer P. Quinidine :@0.524254:0.150111:0.906793:0.150111:0.906793:0.136788:0.524254:0.136788:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
revisited. :@0.554562:0.163905:0.618362:0.163905:0.618362:0.150582:0.554562:0.150582:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
The American Journal of Medicine. :@0.632883:0.163905:0.906160:0.163905:0.906160:0.150817:0.632883:0.150817:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2009;122:317-21.:@0.554562:0.177699:0.668751:0.177699:0.668751:0.164375:0.554562:0.164375:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6.   Snyman  Jr,  ed.  anti-arrhythmics. :@0.524254:0.191492:0.787319:0.191492:0.787319:0.178169:0.524254:0.178169:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Monthly Index of :@0.789936:0.191492:0.906108:0.191492:0.906108:0.178404:0.789936:0.178404:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Medical Specialities.:@0.554545:0.205286:0.683068:0.205286:0.683068:0.192198:0.554545:0.192198:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.683068:0.205286:0.686694:0.205286:0.686694:0.191151:0.683068:0.191151:0.000000
2011;51(8):108-11.:@0.686694:0.205286:0.809948:0.205286:0.809948:0.191963:0.686694:0.191963:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
antiHYPertensives:@0.524242:0.238677:0.757819:0.238677:0.757819:0.217123:0.524242:0.217123:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the antihypertensive agents comprise a group of :@0.524242:0.252695:0.907262:0.252695:0.907262:0.237707:0.524242:0.237707:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
agents with a vast array of differing mechanisms :@0.524242:0.267816:0.907300:0.267816:0.907300:0.252827:0.524242:0.252827:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of action to decrease blood pressure. according :@0.524242:0.282937:0.907243:0.282937:0.907243:0.267948:0.524242:0.267948:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
to the  WHo/ISH guidelines on hypertension, :@0.524242:0.298058:0.907243:0.298058:0.907243:0.283069:0.524242:0.283069:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
hypertension remains inadequately managed :@0.524242:0.313179:0.907243:0.313179:0.907243:0.298190:0.524242:0.298190:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
worldwide. treating hypertension can lead to a :@0.524242:0.328300:0.907262:0.328300:0.907262:0.313311:0.524242:0.313311:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
40% reduction in the risk of stroke and around :@0.524242:0.343421:0.907300:0.343421:0.907300:0.328432:0.524242:0.328432:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
15% in the risk of myocardial infarction. the WHo/:@0.524242:0.358542:0.903029:0.358542:0.903029:0.343553:0.524242:0.343553:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
ISH guidelines further state that the majority of :@0.524242:0.373663:0.907281:0.373663:0.907281:0.358674:0.524242:0.358674:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
cerebrovascular events and half of ischaemic :@0.524242:0.388784:0.907262:0.388784:0.907262:0.373795:0.524242:0.373795:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
heart disease are attributable to a systolic blood :@0.524242:0.403905:0.907204:0.403905:0.907204:0.388916:0.524242:0.388916:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
pressure of more than 155 mmHg, making :@0.524242:0.419025:0.907281:0.419025:0.907281:0.404037:0.524242:0.404037:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
isolated systolic hypertension a prominent goal :@0.524242:0.434146:0.907262:0.434146:0.907262:0.419158:0.524242:0.419158:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
for therapeutic intervention.:@0.524242:0.449267:0.739891:0.449267:0.739891:0.434279:0.524242:0.434279:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1:@0.739888:0.443474:0.745363:0.443474:0.745363:0.434736:0.739888:0.434736:0.000000
Centrally-acting sympathetic :@0.524242:0.473814:0.849285:0.473814:0.849285:0.452260:0.524242:0.452260:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
nervous system inhibitors :@0.524242:0.488931:0.815238:0.488931:0.815238:0.467376:0.524242:0.467376:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Centrally-acting:@0.524242:0.502953:0.654975:0.502953:0.654975:0.487964:0.524242:0.487964:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
sympathetic:@0.695595:0.502953:0.796849:0.502953:0.796849:0.487964:0.695595:0.487964:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
nervous:@0.837470:0.502953:0.903029:0.502953:0.903029:0.487964:0.837470:0.487964:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
system inhibitors can be classified as either :@0.524242:0.518074:0.907281:0.518074:0.907281:0.503085:0.524242:0.503085:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
first-generation (methyldopa) or second-:@0.524242:0.533194:0.903029:0.533194:0.903029:0.518206:0.524242:0.518206:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
generation (moxonidine). the antihypertensive :@0.524242:0.548315:0.907243:0.548315:0.907243:0.533327:0.524242:0.533327:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
effect of methyldopa is attributed to its action :@0.524242:0.563436:0.907262:0.563436:0.907262:0.548448:0.524242:0.548448:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
on the α -receptors (blockers) in  the  central :@0.524242:0.578557:0.907244:0.578554:0.907244:0.563565:0.524242:0.563569:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2:@0.600886:0.581580:0.606360:0.581580:0.606360:0.572842:0.600886:0.572842:0.000000
nervous system. Here it is converted to its :@0.524243:0.593675:0.907301:0.593675:0.907301:0.578686:0.524243:0.578686:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
active metabolites, which are able to bind :@0.524243:0.608796:0.907263:0.608796:0.907263:0.593807:0.524243:0.593807:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
to the α -receptors, preventing noradrenalin :@0.524243:0.623917:0.907244:0.623915:0.907244:0.608926:0.524243:0.608928:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2:@0.597538:0.626941:0.603012:0.626941:0.603012:0.618202:0.597538:0.618202:0.000000
from binding. In contrast, the antihypertensive :@0.524243:0.639036:0.907244:0.639036:0.907244:0.624047:0.524243:0.624047:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
action  of moxonidine is  due  the  sympatho-:@0.524243:0.654157:0.903011:0.654157:0.903011:0.639168:0.524243:0.639168:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
inhibitory action of binding to the imidazoline :@0.524243:0.669277:0.907283:0.669277:0.907283:0.654289:0.524243:0.654289:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
receptor’s subtype 1.  :@0.524243:0.684398:0.714521:0.684396:0.714521:0.669407:0.524243:0.669410:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2-4:@0.695342:0.678611:0.710307:0.678611:0.710307:0.669873:0.695342:0.669873:0.000000:0.000000:0.000000
Methyldopa :@0.524242:0.708952:0.658451:0.708952:0.658451:0.687397:0.524242:0.687397:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Indications::@0.524242:0.727136:0.624629:0.727136:0.624629:0.710745:0.524242:0.710745:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5:@0.624627:0.721352:0.630854:0.721352:0.630854:0.711796:0.624627:0.711796:0.000000
essential hypertension:@0.524242:0.742256:0.696153:0.742256:0.696153:0.727268:0.524242:0.727268:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Dosage::@0.524242:0.761545:0.593668:0.761545:0.593668:0.745154:0.524242:0.745154:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5:@0.593668:0.755759:0.599894:0.755759:0.599894:0.746203:0.593668:0.746203:0.000000
adults: Initial: 0.25 g 2-3 times  daily   First :@0.524242:0.776664:0.907243:0.776664:0.907243:0.761675:0.524242:0.761675:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.850978:0.776148:0.859791:0.776148:0.859791:0.761463:0.850978:0.761463:0.000000
48  hrs, increase at no less than 48-hr interval :@0.524242:0.791785:0.907243:0.791785:0.907243:0.776796:0.524242:0.776796:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
until adequate response    usually 0.5-2 g daily :@0.524242:0.806905:0.907262:0.806905:0.907262:0.791917:0.524242:0.791917:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.724882:0.806390:0.733695:0.806390:0.733695:0.791705:0.724882:0.791705:0.000000
 :@0.903029:0.806905:0.907243:0.806905:0.907243:0.791917:0.903029:0.791917:0.000000
:@0.524242:0.821510:0.533055:0.821510:0.533055:0.806826:0.524242:0.806826:0.000000
  Children:  Initial  10  mg/kg  body  mass  daily  in :@0.533055:0.822026:0.907185:0.822026:0.907185:0.807038:0.533055:0.807038:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
divided doses:@0.524242:0.837147:0.630325:0.837147:0.630325:0.822159:0.524242:0.822159:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Contraindications::@0.524242:0.856435:0.682030:0.856435:0.682030:0.840045:0.524242:0.840045:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5:@0.682027:0.850647:0.688254:0.850647:0.688254:0.841091:0.682027:0.841091:0.000000
acute  hepatic  disorder    Pregnancy    Pheo-:@0.524242:0.871552:0.903029:0.871552:0.903029:0.856563:0.524242:0.856563:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.724267:0.871036:0.733080:0.871036:0.733080:0.856352:0.724267:0.856352:0.000000
:@0.837296:0.871036:0.846110:0.871036:0.846110:0.856352:0.837296:0.856352:0.000000
chromocytoma:@0.524242:0.886673:0.642813:0.886673:0.642813:0.871684:0.524242:0.871684:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Side effects::@0.524242:0.905961:0.627458:0.905961:0.627458:0.889570:0.524242:0.889570:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5:@0.627456:0.900175:0.633683:0.900175:0.633683:0.890619:0.627456:0.890619:0.000000
drowsiness :@0.524242:0.921079:0.615605:0.921079:0.615605:0.906091:0.524242:0.906091:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.628458:0.920563:0.637271:0.920563:0.637271:0.905879:0.628458:0.905879:0.000000
 CnS-depression, especially in :@0.637271:0.921079:0.907242:0.921079:0.907242:0.906091:0.637271:0.906091:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the presence of renal  failure   Changes in :@0.524242:0.936637:0.907262:0.936637:0.907262:0.921648:0.524242:0.921648:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.786150:0.936121:0.794963:0.936121:0.794963:0.921437:0.786150:0.921437:0.000000